Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription Articles published in Cancer Retrieve available abstracts of 119 articles: HTML format

Single Articles

April 2024
1. JABBOUR E, Haddad FG, Sasaki K, Carter BZ, et al
   Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
   Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317.
   PubMed     Abstract available
   
   
   
2. LOKE J, Labopin M, Craddock C, Socie G, et al
   Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party
   Cancer. 2024 Apr 6. doi: 10.1002/cncr.35308.
   PubMed     Abstract available
   
   
   
3. WANG X, Zhang B, Zhang Q, Zhou H, et al
   Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
   Cancer. 2024 Apr 5. doi: 10.1002/cncr.35316.
   PubMed     Abstract available
   
   
   March 2024
4. DUFFY C, Hunger SP, Bhakta N, Denburg AE, et al
   Curing pediatric cancer: A global view. Examples from acute lymphoblastic leukemia.
   Cancer. 2024 Mar 29. doi: 10.1002/cncr.35290.
   PubMed    
   
   
   
5. HUANG R, He H, Xu X, Lin X, et al
   Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
   Cancer. 2024 Mar 12. doi: 10.1002/cncr.35278.
   PubMed     Abstract available
   
   
   
6. ROSENBERG SM, McCue S, He J, Lafky JM, et al
   Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
   Cancer. 2024;130:750-769.
   PubMed     Abstract available
   
   
   February 2024
7. DINH A, Savoy JM, Kontoyiannis DP, Takahashi K, et al
   Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
   Cancer. 2024 Feb 10. doi: 10.1002/cncr.35251.
   PubMed     Abstract available
   
   
   
8. GUAN F, Yang L, Chen Y, Shi J, et al
   Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study.
   Cancer. 2024 Feb 5. doi: 10.1002/cncr.35232.
   PubMed     Abstract available
   
   
   January 2024
9. SEDETA E, Jemal A, Nisotel L, Sung H, et al
   Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
   Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
   PubMed     Abstract available
   
   
   December 2023
10. PALANDRI F, Palumbo GA, Benevolo G, Iurlo A, et al
    Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
    Cancer. 2023 Dec 28. doi: 10.1002/cncr.35156.
    PubMed     Abstract available
    
    
    November 2023
11. YANG X, Yang L, Luo A, Liu S, et al
    IKZF3 polymorphisms contribute to the increased risk of acute lymphoblastic leukemia in children.
    Cancer. 2023 Nov 29. doi: 10.1002/cncr.35129.
    PubMed     Abstract available
    
    
    
12. RUIZ J, Li Y, Cao L, Huang YV, et al
    Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35109.
    PubMed     Abstract available
    
    
    
13. NIERENGARTEN MB
    New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:3356.
    PubMed    
    
    
    October 2023
14. PULLARKAT V, Chen LS, Palmer J, Zhang J, et al
    A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics.
    Cancer. 2023 Oct 28. doi: 10.1002/cncr.35077.
    PubMed     Abstract available
    
    
    
15. GUPTA DG, Varma N, Abdulkadir SA, Sreedharanunni S, et al
    A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
    Cancer. 2023 Oct 11. doi: 10.1002/cncr.35051.
    PubMed     Abstract available
    
    
    
16. EFFICACE F, Cottone F, Yanez B, Kota V, et al
    Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
    Cancer. 2023 Oct 6. doi: 10.1002/cncr.35021.
    PubMed     Abstract available
    
    
    September 2023
17. SASAKI K, Haddad FG, Short NJ, Jain N, et al
    Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
    Cancer. 2023 Sep 28. doi: 10.1002/cncr.35038.
    PubMed     Abstract available
    
    
    
18. NIERENGARTEN MB
    Children living in extreme poverty face a greater risk of acute lymphoblastic leukemia relapse.
    Cancer. 2023;129:2764.
    PubMed    
    
    
    
19. GIEBEL S, Labopin M, Salmenniemi U, Socie G, et al
    Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the
    Cancer. 2023 Sep 1. doi: 10.1002/cncr.35004.
    PubMed     Abstract available
    
    
    August 2023
20. BROWN JC, Ma C, Shi Q, Zemla T, et al
    Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).
    Cancer. 2023 Aug 31. doi: 10.1002/cncr.35007.
    PubMed     Abstract available
    
    
    
21. TIBES R, Kosiorek HE, Dueck AC, Palmer J, et al
    Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
    Cancer. 2023;129:2321-2330.
    PubMed     Abstract available
    
    
    July 2023
22. GUPTA DG, Varma N, Sharma P, Truica MI, et al
    Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India.
    Cancer. 2023 Jul 27. doi: 10.1002/cncr.34957.
    PubMed     Abstract available
    
    
    
23. NUHOGLU KANTARCI E, Tolgay E, Eskazan AE
    Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient.
    Cancer. 2023 Jul 3. doi: 10.1002/cncr.34938.
    PubMed    
    
    
    
24. MA YY, Wei ZL, Xu YJ, Shi JM, et al
    Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study.
    Cancer. 2023;129:2013-2022.
    PubMed     Abstract available
    
    
    June 2023
25. TIRIBELLI M, Latagliata R, Breccia M, Capodanno I, et al
    Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
    Cancer. 2023 Jun 24. doi: 10.1002/cncr.34923.
    PubMed     Abstract available
    
    
    
26. VENUGOPAL S, Taylor J
    Trying to outRun-DIC in KMT2Ar AML: It's tricky.
    Cancer. 2023;129:1797-1799.
    PubMed    
    
    
    
27. AL HAMED R, Ngoya M, Galimard JE, Sengeloev H, et al
    Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
    Cancer. 2023 Jun 2. doi: 10.1002/cncr.34843.
    PubMed     Abstract available
    
    
    May 2023
28. LIAO H, Xu Y, Meng Q, Mao Z, et al
    A convolutional neural network-based, quantitative complete blood count scattergram-mapping framework promptly screens acute promyelocytic leukemia with high sensitivity.
    Cancer. 2023 May 31. doi: 10.1002/cncr.34890.
    PubMed     Abstract available
    
    
    
29. FRANCO S, Geng X, Korostyshevskiy V, Karp JE, et al
    Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia.
    Cancer. 2023 May 31. doi: 10.1002/cncr.34894.
    PubMed     Abstract available
    
    
    
30. NIERENGARTEN MB
    Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:1466.
    PubMed    
    
    
    
31. HADDAD FG, Bidikian A, Issa GC
    Reply to "Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!".
    Cancer. 2023 May 3. doi: 10.1002/cncr.34834.
    PubMed    
    
    
    
32. ESKAZAN AE
    Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!
    Cancer. 2023 May 3. doi: 10.1002/cncr.34833.
    PubMed    
    
    
    April 2023
33. FORAN JM, Sun Z, Lai C, Fernandez HF, et al
    Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34807.
    PubMed     Abstract available
    
    
    
34. DUONG VH, Ruppert AS, Mims AS, Borate U, et al
    Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
    Cancer. 2023 Apr 20. doi: 10.1002/cncr.34780.
    PubMed     Abstract available
    
    
    
35. GORDON MJ, Jones JE, George B, Peterson C, et al
    Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
    Cancer. 2023 Apr 5. doi: 10.1002/cncr.34787.
    PubMed     Abstract available
    
    
    March 2023
36. CHRISTAKOPOULOS GE, Walker KN, Smith J, Takemoto CM, et al
    Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods.
    Cancer. 2023 Mar 21. doi: 10.1002/cncr.34751.
    PubMed     Abstract available
    
    
    
37. ZHANG H, Wan Y, Wang H, Cai J, et al
    Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study.
    Cancer. 2023 Mar 21. doi: 10.1002/cncr.34741.
    PubMed     Abstract available
    
    
    
38. NGUYEN D, Kantarjian HM, Short NJ, Qiao W, et al
    Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
    Cancer. 2023 Mar 9. doi: 10.1002/cncr.34728.
    PubMed     Abstract available
    
    
    
39. HADDAD FG, Kantarjian HM, Bidikian A, Jabbour EJ, et al
    Association between bariatric surgery and outcomes in chronic myeloid leukemia.
    Cancer. 2023 Mar 7. doi: 10.1002/cncr.34725.
    PubMed     Abstract available
    
    
    
40. XIE M, Shi T, Jiang Q, Jia Y, et al
    Chemotherapy with the use of next-generation TKIs based on MRD has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Cancer. 2023 Mar 7. doi: 10.1002/cncr.34710.
    PubMed     Abstract available
    
    
    February 2023
41. LOGAN AC
    Lower leukemia burden maximizes the impact of blinatumomab therapy.
    Cancer. 2023 Feb 24. doi: 10.1002/cncr.34666.
    PubMed    
    
    
    
42. QUEUDEVILLE M, Stein AS, Locatelli F, Ebinger M, et al
    Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Cancer. 2023 Feb 24. doi: 10.1002/cncr.34667.
    PubMed     Abstract available
    
    
    
43. CASTELLANOS MI, Oluyomi AO, Chambers TM, Gramatges MM, et al
    Ethnic disparities in childhood leukemia survival by border residence: A Texas population-based analysis.
    Cancer. 2023 Feb 21. doi: 10.1002/cncr.34636.
    PubMed     Abstract available
    
    
    
44. ARISTIZABAL P, Thornburg CD, Young J
    At the border: A call to action for health equity for children with leukemia.
    Cancer. 2023 Feb 21. doi: 10.1002/cncr.34629.
    PubMed    
    
    
    
45. NIERENGARTEN MB
    Poorer outcomes in young adult Black patients with acute myeloid leukemia.
    Cancer. 2023;129:493.
    PubMed    
    
    
    
46. BODDU PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, et al
    A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
    Cancer. 2023;129:580-589.
    PubMed     Abstract available
    
    
    
47. GUPTA DG, Varma N, Kumar A, Naseem S, et al
    Genomic and proteomic characterization of Philadelphia-like B-lineage acute lymphoblastic leukemia: A report of Indian patients.
    Cancer. 2023 Feb 3. doi: 10.1002/cncr.34665.
    PubMed     Abstract available
    
    
    
48. 
    Off-the-shelf T cells deliver remissions for certain kinds of leukemia.
    Cancer. 2023;129:332.
    PubMed    
    
    
    January 2023
49. SASAKI K, Ravandi F, Kadia TM, Borthakur G, et al
    Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
    Cancer. 2023 Jan 30. doi: 10.1002/cncr.34609.
    PubMed     Abstract available
    
    
    
50. WONG CI, Vannatta K, Gilleland Marchak J, Quade EV, et al
    Preventable harm because of outpatient medication errors among children with leukemia and lymphoma: A multisite longitudinal assessment.
    Cancer. 2023 Jan 27. doi: 10.1002/cncr.34651.
    PubMed     Abstract available
    
    
    
51. HARRIS RD, Bernhardt MB, Zobeck MC, Taylor OA, et al
    Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate.
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34646.
    PubMed     Abstract available
    
    
    
52. TODISCO E, Papayannidis C, Fracchiolla N, Petracci E, et al
    AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34608.
    PubMed     Abstract available
    
    
    
53. EL-JAWAHRI A, Luskin MR, Greer JA, Traeger L, et al
    Psychological mobile app for patients with acute myeloid leukemia (AML): A pilot randomized clinical trial.
    Cancer. 2023 Jan 18. doi: 10.1002/cncr.34645.
    PubMed     Abstract available
    
    
    
54. PORTUGUESE AJ, Albittar A, Gooley TH, Deeg HJ, et al
    Transplantation for myeloid neoplasms with antecedent solid tumor.
    Cancer. 2023;129:142-150.
    PubMed     Abstract available
    
    
    December 2022
55. KENT A, Pollyea DA
    Top advances of the year: Leukemia.
    Cancer. 2022 Dec 30. doi: 10.1002/cncr.34619.
    PubMed     Abstract available
    
    
    
56. SHUAI W, Zuo Z, Li N, Garces S, et al
    ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
    Cancer. 2022 Dec 29. doi: 10.1002/cncr.34616.
    PubMed     Abstract available
    
    
    
57. BADAR T, Litzow MR, Shallis RM, Patel A, et al
    Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia.
    Cancer. 2022 Dec 21. doi: 10.1002/cncr.34604.
    PubMed     Abstract available
    
    
    
58. YU CH, Jou ST, Su YH, Coustan-Smith E, et al
    Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
    Cancer. 2022 Dec 20. doi: 10.1002/cncr.34606.
    PubMed     Abstract available
    
    
    
59. ESPINOZA D, Blanco Lopez JG, Vasquez R, Fu L, et al
    How should childhood acute lymphoblastic leukemia relapses in low-income and middle-income countries be managed: The AHOPCA-ALL study group experience.
    Cancer. 2022 Dec 12. doi: 10.1002/cncr.34572.
    PubMed     Abstract available
    
    
    
60. CHENG F, Zeng F, Li Q, Cui Z, et al
    Reply to "Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!".
    Cancer. 2022 Dec 8. doi: 10.1002/cncr.34578.
    PubMed    
    
    
    
61. ESKAZAN AE
    Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!
    Cancer. 2022 Dec 8. doi: 10.1002/cncr.34577.
    PubMed    
    
    
    
62. ZENG Z, Maiti A, Herbrich S, Cai T, et al
    Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
    Cancer. 2022 Dec 7. doi: 10.1002/cncr.34566.
    PubMed     Abstract available
    
    
    
63. BAZINET A, Darbaniyan F, Kadia TM, Venugopal S, et al
    A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
    Cancer. 2022 Dec 2. doi: 10.1002/cncr.34564.
    PubMed     Abstract available
    
    
    November 2022
64. DUDLEY IM, Sunguc C, Heymer EJ, Winter DL, et al
    Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study.
    Cancer. 2022 Nov 29. doi: 10.1002/cncr.34561.
    PubMed     Abstract available
    
    
    
65. SHALLIS RM, Daver NG, Altman JK, Hasserjian RP, et al
    TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
    Cancer. 2022 Nov 17. doi: 10.1002/cncr.34535.
    PubMed     Abstract available
    
    
    
66. HAN H, Yao Y, Wang H, Zhou M, et al
    Landscape and clinical impact of NOTCH mutations in newly diagnosed acute myeloid leukemia.
    Cancer. 2022 Nov 12. doi: 10.1002/cncr.34534.
    PubMed     Abstract available
    
    
    
67. ORGEL E, Mittelman SD
    From soup to nuts: Obesity impairs chemotherapy during early and late phases of acute lymphoblastic leukemia treatment.
    Cancer. 2022 Nov 12. doi: 10.1002/cncr.34528.
    PubMed    
    
    
    
68. WADHWA A, Chen Y, Hageman L, Hoppmann AL, et al
    Body mass index during maintenance therapy and relapse risk in children with acute lymphoblastic leukemia: A Children's Oncology Group report.
    Cancer. 2022 Nov 12. doi: 10.1002/cncr.34529.
    PubMed     Abstract available
    
    
    
69. LIPSKY AH, Lamanna N
    Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
    Cancer. 2022 Nov 3. doi: 10.1002/cncr.34510.
    PubMed     Abstract available
    
    
    
70. HA H, Kim HJ, Park JH, Shin A, et al
    Epidemiologic outlook of therapy-related myeloid neoplasms and selection of high-risk patients: A Korean nationwide study.
    Cancer. 2022;128:3888-3896.
    PubMed     Abstract available
    
    
    October 2022
71. YE MT, Wang Y, Zuo Z, Calin S, et al
    Integrated clinical genotype-phenotype characteristics of early T-cell precursor acute lymphoblastic leukemia.
    Cancer. 2022 Oct 25. doi: 10.1002/cncr.34515.
    PubMed     Abstract available
    
    
    
72. PASTORE F, Pastore A, Rothenberg-Thurley M, Metzeler KH, et al
    Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis.
    Cancer. 2022 Oct 22. doi: 10.1002/cncr.34495.
    PubMed     Abstract available
    
    
    
73. PATEL PA, DeGroote NP, Jackson K, Cash T, et al
    Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia.
    Cancer. 2022 Oct 13. doi: 10.1002/cncr.34476.
    PubMed     Abstract available
    
    
    
74. JIA R, Ji M, Li G, Xia Y, et al
    Subclones of bone marrow CD34(+) cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy.
    Cancer. 2022 Oct 5. doi: 10.1002/cncr.34481.
    PubMed     Abstract available
    
    
    
75. CHENG F, Zeng F, Li Q, Cui Z, et al
    Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia.
    Cancer. 2022 Oct 1. doi: 10.1002/cncr.34478.
    PubMed     Abstract available
    
    
    September 2022
76. NAGLER A, Labopin M, Arat M, Remenyi P, et al
    Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelat
    Cancer. 2022 Sep 15. doi: 10.1002/cncr.34452.
    PubMed     Abstract available
    
    
    
77. BALL S, Knepper TC, Deutsch YE, Samra W, et al
    Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.
    Cancer. 2022 Sep 15. doi: 10.1002/cncr.34459.
    PubMed     Abstract available
    
    
    July 2022
78. ALVAREZ-LARRAN A, Garrote M, Ferrer-Marin F, Perez-Encinas M, et al
    Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Cancer. 2022;128:2441-2448.
    PubMed     Abstract available
    
    
    June 2022
79. KENNEDY KR, Turner JH, MacDonald WBG, Claringbold PG, et al
    Long-term survival and toxicity in patients with neuroendocrine tumors treated with (177) Lu-octreotate peptide radionuclide therapy.
    Cancer. 2022;128:2182-2192.
    PubMed     Abstract available
    
    
    May 2022
80. LOKE J, Labopin M, Craddock C, Cornelissen JJ, et al
    Additional cytogenetic features determines outcome in patients allografted for TP53 mutant acute myeloid leukemia.
    Cancer. 2022 May 25. doi: 10.1002/cncr.34268.
    PubMed     Abstract available
    
    
    April 2022
81. SHESHADRI A, Goizueta AA, Shannon VR, London D, et al
    Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.
    Cancer. 2022 Apr 22. doi: 10.1002/cncr.34229.
    PubMed     Abstract available
    
    
    
82. DINARDO CD, Garcia-Manero G, Kantarjian HM
    Time to blur the blast boundaries.
    Cancer. 2022;128:1568-1570.
    PubMed    
    
    
    
83. O'ROURKE K
    CD123 expression linked to high-risk disease in children with acute myeloid leukemia.
    Cancer. 2022;128:1357-1358.
    PubMed    
    
    
    March 2022
84. CHEN X, Huang J, Xu N, Fan Z, et al
    A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.
    Cancer. 2022 Mar 22. doi: 10.1002/cncr.34182.
    PubMed     Abstract available
    
    
    February 2022
85. CONTER V, Schrappe M, Escherich G
    Does the Y chromosome play a role for outcome in childhood acute lymphoblastic leukemia?
    Cancer. 2022 Feb 24. doi: 10.1002/cncr.34147.
    PubMed    
    
    
    
86. GUPTA S, Teachey DT, Chen Z, Rabin KR, et al
    Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report.
    Cancer. 2022 Feb 24. doi: 10.1002/cncr.34150.
    PubMed     Abstract available
    
    
    
87. CHOW EJ, Aplenc R, Vrooman LM, Doody DR, et al
    Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
    Cancer. 2022;128:788-796.
    PubMed     Abstract available
    
    
    
88. O'ROURKE K
    Study examines oral health of patients with leukemia.
    Cancer. 2022;128:430-431.
    PubMed    
    
    
    December 2021
89. GARCIA KA, Cherian S, Stevenson PA, Martino CH, et al
    Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
    Cancer. 2021 Dec 21. doi: 10.1002/cncr.34073.
    PubMed     Abstract available
    
    
    
90. UNGER JM, Beauchemin M, Hershman DL
    Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years.
    Cancer. 2021;127:4574-4584.
    PubMed     Abstract available
    
    
    November 2021
91. GUPTA S, Sutradhar R, Pequeno P, Hitzler JK, et al
    Risks of late mortality and morbidity among survivors of childhood acute leukemia with Down syndrome: A population-based cohort study.
    Cancer. 2021 Nov 30. doi: 10.1002/cncr.34042.
    PubMed     Abstract available
    
    
    October 2021
92. NIERENGARTEN MB
    Higher mortality risk in African American women with triple-negative breast cancer.
    Cancer. 2021;127:3712-3713.
    PubMed    
    
    
    
93. CHEMAITILLY W, Li Z, Brinkman TM, Delaney A, et al
    Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences.
    Cancer. 2021 Oct 13. doi: 10.1002/cncr.33969.
    PubMed     Abstract available
    
    
    
94. ALDOSS I, Otoukesh S, Zhang J, Mokhtari S, et al
    Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
    Cancer. 2021 Oct 11. doi: 10.1002/cncr.33967.
    PubMed     Abstract available
    
    
    
95. KANTARJIAN HM, Jain N, Garcia-Manero G, Welch MA, et al
    The cure of leukemia through the optimist's prism.
    Cancer. 2021 Oct 6. doi: 10.1002/cncr.33933.
    PubMed     Abstract available
    
    
    September 2021
96. JAMY OH, Dhir A, Costa LJ, Xavier AC, et al
    Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis.
    Cancer. 2021 Sep 8. doi: 10.1002/cncr.33914.
    PubMed     Abstract available
    
    
    August 2021
97. NELSON AM, Amonoo HL, Kavanaugh AR, Webb JA, et al
    Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial.
    Cancer. 2021 Aug 30. doi: 10.1002/cncr.33886.
    PubMed     Abstract available
    
    
    
98. KENNEDY VE, Keegan THM, Li Q, Maguire FB, et al
    Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era.
    Cancer. 2021 Aug 26. doi: 10.1002/cncr.33873.
    PubMed     Abstract available
    
    
    
99. KANTARJIAN HM, Begna KH, Altman JK, Goldberg SL, et al
    Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
    Cancer. 2021 Aug 23. doi: 10.1002/cncr.33828.
    PubMed     Abstract available
    
    
    
100. KLISOVIC RB, Leung WH, Brugger W, Dirnberger-Hertweck M, et al
     A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
     Cancer. 2021 Aug 3. doi: 10.1002/cncr.33796.
     PubMed     Abstract available
     
     
     
101. MAITI A, DiNardo CD, Qiao W, Kadia TM, et al
     Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
     Cancer. 2021 Aug 3. doi: 10.1002/cncr.33814.
     PubMed     Abstract available
     
     
     July 2021
102. 
     Erratum to "Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL113
     Cancer. 2021 Jul 22. doi: 10.1002/cncr.33597.
     PubMed    
     
     
     
103. KIM K, Maiti A, Loghavi S, Pourebrahim R, et al
     Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
     Cancer. 2021 Jul 13. doi: 10.1002/cncr.33689.
     PubMed     Abstract available
     
     
     June 2021
104. VENUGOPAL S, Shoukier M, Konopleva M, Dinardo CD, et al
     Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
     Cancer. 2021 Jun 28. doi: 10.1002/cncr.33675.
     PubMed     Abstract available
     
     
     
105. SAXENA K, Herbrich SM, Pemmaraju N, Kadia TM, et al
     A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
     Cancer. 2021 Jun 25. doi: 10.1002/cncr.33690.
     PubMed     Abstract available
     
     
     
106. HOPPMANN AL, Chen Y, Landier W, Hageman L, et al
     Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1.
     Cancer. 2021 Jun 23. doi: 10.1002/cncr.33760.
     PubMed     Abstract available
     
     
     
107. SASAKI K, Kantarjian HM, Morita K, Short NJ, et al
     Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
     Cancer. 2021 Jun 17. doi: 10.1002/cncr.33655.
     PubMed     Abstract available
     
     
     May 2021
108. NGUYEN HTK, Terao MA, Green DM, Pui CH, et al
     Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management.
     Cancer. 2021 May 25. doi: 10.1002/cncr.33609.
     PubMed     Abstract available
     
     
     
109. BORTHAKUR G, Odenike O, Aldoss I, Rizzieri DA, et al
     A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
     Cancer. 2021 May 2. doi: 10.1002/cncr.33590.
     PubMed     Abstract available
     
     
     
110. PRINTZ C
     First Person Profile: Cheryl Willman, MD: As director and CEO of the University of New Mexico Comprehensive Cancer Center, Dr. Willman has led major health equity initiatives while making pioneering discoveries in precision medicine.
     Cancer. 2021;127:1357-1358.
     PubMed    
     
     
     April 2021
111. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Sasaki K, Masarova L, et al
     Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
     Cancer. 2021 Apr 29. doi: 10.1002/cncr.33622.
     PubMed     Abstract available
     
     
     
112. IIJIMA M, Liu W, Panetta JC, Hudson MM, et al
     Association between obesity and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated only with chemotherapy.
     Cancer. 2021 Apr 29. doi: 10.1002/cncr.33624.
     PubMed     Abstract available
     
     
     
113. ALLEN OS, Kim N, Morillo J, Smith CB, et al
     Assessment of prognostic understanding, perceived goals of care, and quality of life in hospitalized patients with leukemia or multiple myeloma.
     Cancer. 2021 Apr 23. doi: 10.1002/cncr.33599.
     PubMed     Abstract available
     
     
     
114. JAMY OH, Godby R, Dhir A, Costa LJ, et al
     Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United States.
     Cancer. 2021 Apr 23. doi: 10.1002/cncr.33593.
     PubMed     Abstract available
     
     
     
115. PEMMARAJU N
     A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic.
     Cancer. 2021 Apr 23. doi: 10.1002/cncr.33594.
     PubMed    
     
     
     
116. MORITA K, Kantarjian HM, Sasaki K, Issa GC, et al
     Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
     Cancer. 2021 Apr 6. doi: 10.1002/cncr.33539.
     PubMed     Abstract available
     
     
     
117. CALDWELL KJ, Budhraja A, Opferman JT, Pui CH, et al
     Activity of venetoclax against relapsed acute undifferentiated leukemia.
     Cancer. 2021 Apr 6. doi: 10.1002/cncr.33531.
     PubMed    
     
     
     
118. SASAKI K, Ravandi F, Kadia TM, DiNardo CD, et al
     De novo acute myeloid leukemia: A population- based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017.
     Cancer. 2021 Apr 5. doi: 10.1002/cncr.33458.
     PubMed     Abstract available
     
     
     
119. BENCOMO-ALVAREZ AE, Gonzalez MA, Rubio AJ, Olivas IM, et al
     Ethnic and border differences on blood cancer presentation and outcomes: A Texas population-based study.
     Cancer. 2021;127:1068-1079.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.